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b2-microglobulin induces MMP-1 but not TIMP-1 expression cent autopsy series have demonstrated that 90% of pa-
in human synovial fibroblasts. tients on hemodialysis (HD) for over five years had
Background. b2-Microglobulin (b2m) amyloidosis is a de- pathologic evidence of the disease [2, 3]. The diseasestructive articular disease that causes significant morbidity in
initially manifests with symptoms and findings localizedpatients undergoing hemodialysis. The amyloid deposits con-
to joints: carpal tunnel syndrome, bone cysts only neartain b2m, some of which is altered with advanced glycation end
products (AGE-b2m). The deposits are located principally in joints, synovial hypertrophy, and spondyloarthropathy
joint structures, with adjacent degradation of cartilage and bone. [1, 4]. Lesions in the shafts of long bones are not observed,
We hypothesized that one of the mechanisms by which b2m implying that structures in the joint such as synoviuminduces joint destruction is to induce the release of matrix metal-
are important for amyloid formation. Pathologic analysisloproteinase-1 (MMP-1), but not tissue inhibitor of metallopro-
reveals the earliest sites of deposition to be the surfaceteinase-1 (TIMP-1), from synovial fibroblasts.
Methods. To test this hypothesis and determine the role of of articular cartilage, followed by the subintima of the
AGE-b2m, we incubated human osteoarthritic synovial fibro- synovial membrane and collagenous connective tissue
blasts in the presence and absence of b2m and AGE-b2m and of the joint capsule. With increasing time, an erosivemeasured the release of interstitial collagenase (MMP-1) and/or
arthropathy develops: loss of articular cartilage, fibrousTIMP-1 by enzyme-linked immunosorbent assay and Northern
blot analysis. and fibrocartilaginous replacement of the articular sur-
Results. b2m and AGE-b2m at 10 and 25 mg/mL induced the face, and subchondral bone sclerosis [5, 6]. On micro-
release of MMP-1 from human osteoarthritic synovial fibro- scopic analysis, b2m is the major constituent of the amy-blasts at 24 hours. In contrast, there was no increased release
loid fibrils, although recent data have shown that some ofof TIMP-1, leading to an increase in the MMP-1/TIMP-1 ratio
the b2m is altered with advanced glycation end productsindicative of uncontrolled collagenolysis. A similar dose re-
sponse was observed at 48 hours, except that AGE-b2m had (AGEs) [7, 8].
no effect over control cultures. MMP-1 mRNA expression by Advanced glycation end-products are a heterogeneous
Northern blot analysis paralleled these findings. The source of group of proteins that have been altered with glucosethe fibroblasts did not alter the results. Finally, we demonstrated
or carbohydrate adducts. The alteration of proteins withthat doxycycline, a treatment for arthritis, can inhibit the re-
AGE is increased in diabetes, renal failure, and aginglease of MMP-1 from synovial fibroblasts incubated with b2m.
Conclusion. b2m, at physiologically relevant concentrations, and is hypothesized to account for a variety of disease
induces the release of MMP-1 without concomitant release of states [reviewed in 9]. In vitro studies have demonstrated
TIMP-1 from human synovial fibroblasts, leading to uncon- that AGE-b2m stimulates the chemotaxis of macro-trolled collagenolysis. The alteration of b2m with AGE did not
phage/monocytes preferentially over non–AGE-b2m,alter this effect at 24 hours, but blocked the effect at 48 hours.
with subsequent release of cytokines [7, 8]. In contrast,These findings may account for the tissue destruction seen in
b2m amyloidosis. AGE-b2m inhibited collagen synthesis in skin fibroblasts,
mediated by the receptor for AGE (RAGE) [10]. Au-
b2-Microglobulin (b2m) amyloidosis is a destructive topsy studies of dialysis patients have demonstrated the
articular disease that causes significant morbidity and presence of AGE-b2m only late in the disease course,
mortality in patients receiving dialytic therapy [1]. Re- indicating that AGE alteration of b2m is likely to occur
in situ [11]. Thus, the exact role of AGE-b2m in b2m
amyloidosis remains unknown, but it may be importantKey words: amyloidosis, dialysis amyloid, synovium, matrix metallo-
proteinase, collagenolysis. in late inflammatory reactions.
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vated, even during the first few years of dialysis [12, 13]. cellulose cartridge (Millipore, Bedford, MA, USA),
eliminating solutes with as molecular weight of less thanThe synovial lining is composed, based on morphology
and function, of two cell types: macrophage-like (type A) 1 kD. The filtrate was separated with isoelectric focusing
using five to seven ampholytes (Bio-Rad, Richmond,and fibroblast-like (type B) [14]. Macrophage-like syno-
viocytes have been shown to produce cytokines, espe- CA, USA). Some fractions containing b2m were eluted
through an anion exchange column (Econo Q Cartridge;cially interleukin-1b (IL-1b) and tumor necrosis factor-a
(TNF-a). Fibroblast-like synoviocytes produce matrix Bio-Rad) with a NaCl step gradient. The pure b2m,
shown by silver stained sodium dodecyl sulfate-poly-proteins and metalloproteinases, both of which have been
colocalized to b2m amyloid deposits [15–17]. acrylamide gel electrophoresis (SDS-PAGE), was from
the 45 mmol/L NaCl elute and was assayed by competi-Metalloproteinases are zinc-dependent enzymes that
degrade matrix proteins. Interstitial collagenase, or me- tive radioimmunoassay (Pharmacia Diagnostics, Arling-
ton Heights, IL, USA).talloproteinase-1 (MMP-1), degrades the interstitial col-
lagens at neutral pH, with resultant destruction of articular The b2m was then separated into nonglycated and
endogenous early glycated b2m (AGE-b2m) fractions bycartilage and subchondral bone. The actions of MMP-1
are inhibited, in part, by the naturally occurring inhibitor, affinity chromatography on m-boronate columns nor-
mally used for the detection of glycated hemoglobin,tissue inhibitor of metalloproteinase-1 (TIMP-1). There
is increased expression of both MMP-1 and, to a lesser through an adaptation of the methods of Silver et al [24],
using a 200 mmol/L glycine buffer, pH 8.5. The resultantextent, TIMP-1 in the synovium of patients with osteoar-
thritis (OA) and rheumatoid arthritis [18, 19]. The im- glycated b2m (gb2m; less than 0.1% of total) was re-
moved, and the remaining nonglycated b2m (ngb2m) wasportance of MMP in arthritis is supported by studies
showing that inhibition of MMPs results in an improve- separated into three fractions. The first was incubated in
the presence of glycating buffer [1 3 phosphate-bufferedment in joint pathology and inflammation [20, 21]. Be-
cause of the importance of MMPs in subsequent joint saline (PBS), 200 mmol/L d-glucose, 1.5 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 1 mmol/L ethylenedi-destruction, some investigators feel that the synovial fi-
broblast, which produces most of the MMPs, may be aminetetraacetic acid (EDTA)] at 378C for 60 days and
represents gb2m. The second was similarly incubated butthe initial cell activated in rheumatoid arthritis [14, 22].
Interestingly, there is some similarity between the adja- without the glucose to serve as a control for the long
incubation, and is termed ngb2m. The last fraction wascent joint destruction observed in rheumatoid arthritis
and b2m amyloidosis, suggesting a similar pathophysio- neither incubated nor glycated, and is termed fresh b2m
(fb2m). All three fractions were then run on a Toxigellogic mechanism of joint destruction, despite different
inciting events. column (Pierce, Rockford, IL, USA) to remove any po-
tential contamination from lipopolysaccharide (LPS).We therefore hypothesized that the synovial fibroblast
may be an important cell in the early pathogenesis of For comparison, samples from each isolation step were
run on a 10 to 20% SDS-polyacrylamide gradient gel andb2m amyloidosis. The synovial fibroblast is exposed to
high levels of b2m in the synovial fluid and produces all then electrophoretically transblotted to a nitrocellulose
membrane for Western blot analysis with polyclonal rab-of the proteins (such as glycosaminoglycans) present in
amyloid deposits. Further supporting a role of the syno- bit antihuman b2m IgG (Boehringer Mannheim, India-
napolis, IN, USA) or a monoclonal mouse anti-AGEvial fibroblast in the early pathogenesis of b2m amyloid
is that Nakashima et al were able to generate intact b2m antibody (Alteon, Inc., Ramsey, NJ, USA).
amyloid in tissue cultures of human synovium (predomi-
Isolation of human synovial fibroblastsnately fibroblasts) incubated for three months in a colla-
gen gel matrix [23]. To test our hypothesis and examine Human synovium was obtained from patients undergo-
ing total knee or hip replacement for osteoarthritis. Syno-the role of AGE alteration of b2m, we determined the
effect of physiologic concentrations of b2m and AGE- vial tissue was minced and incubated in collagenase (Wako,
Richmond, VA, USA), followed by trypsin. The super-b2m on synovial fibroblast expression of MMP-1 and its
inhibitor TIMP-1. natant was collected. Collagenase activity was quenched,
and cells were pelleted and placed in a T-25 flask in
Dulbecco’s modified Eagle’s medium (DMEM) with
METHODS
20% fetal bovine serum (FBS) [25]. To characterize the
Isolation and purification of b2m and AGE-b2m cells further, histochemistry for uridine diphosphoglu-
cose dehydrogenase activity (UDPGH) and immuno-Ultrafiltrate from a chronic (25 years) HD patient
with documented b2m amyloidosis was collected during fluorescence for markers specific to fibroblast [vascular
cell adhesion molecule-1 (VCAM-1)] and macrophagehemofiltration with an F-80 polysulfone hollow fiber dia-
lyzer (Fresenius, Ogden, UT, USA). The ultrafiltrate was (CD68) were done at the first and third passes.
Uridine diphosphoglucose dehydrogenase activity isthen concentrated and desalted through a regenerated
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an enzyme that is necessary for the production of proteo- complexed to specific inhibitors such as TIMP-1. How-
ever, it does not recognize MMP-1 bound to nonspecificglycans and is increased several-fold in synovial fibro-
blasts compared with other fibroblasts [26]. Slides were inhibitors such as a-2-macroglobulin, and there is no
cross-reactivity with MMP-3, MMP-5, or MMP-9. Theincubated for 30 minutes in 3 mg/mL UDPG, 0.3 mg/mL
b-nicotinamide adenine dinucleotide (NAD), 0.05 mol/L TIMP-1 assay recognizes total TIMP-1, including free
TIMP-1 and that bound to MMP-1. It does not cross-glycylglycine buffer, 3 mg/mL nitro blue tetrazolium
(NBT), in 30% wt/vol polyvinyl alcohol, pH 7.8, and react with TIMP-2.
were saturated with nitrogen. Negative controls were
Northern blot analysisrun simultaneously by omission of NBT [26]. Immuno-
fluorescence was done by fixing cells with 4% paraform- Human foreskin fibroblasts were incubated in the
presence or absence of phorbol 12-myristate 13-acetatealdehyde, washed in phosphate-buffered saline, Triton
X-100 extracted and blocked with 2% defatted bovine (PMA; 1028 mol/L), and fresh gb2m and ngb2m at 10
mg/mL for 12, 24, and 48 hours. RNA was isolated withserum albumin. Goat polyclonal antihuman VCAM-1
(R&D Systems, Minneapolis, MN, USA) and mouse TRIzol Reagent (Gibco BRL, Grand Island, NY, USA)
per an adaptation of the methods of Chomczynski andmonoclonal antihuman CD68 (Dako Corp., Carpinteria,
CA, USA) were used as the primary antibodies (1:100 Sacchi [27]. Twenty micrograms of total RNA were run
on each lane of an agarose/formaldehyde gel, and thefor 2 h at 378C) as markers for fibroblast and macrophage
activity, respectively [14]. After washing, secondary anti- integrity was confirmed by visualizing 18S and 28S ribo-
somal bands with ultraviolet light. The RNA was trans-bodies (Texas Red-conjugated donkey antigoat and
FITC-conjugated sheep antimouse; both from Jackson ferred to nitrocellulose membranes (Nitrobind, MSI,
MA, USA) and hybridized under high stringency condi-Immunoresearch Labs, West Grove, PA, USA) were
added at 1:200 and incubated for an additional 45 min- tions to radiolabeled cDNA probe for human MMP-1
(kind gift of Dr. Connie Brinckerhoff, Dartmouth Uni-utes at 378C. Cells were washed. Nuclei were stained
with To-Pro-3 stain (Molecular Probes, Eugene, OR, versity) in 50% formamide, 5 3 Denhardt’s solution,
5 3 SSPE, and salmon sperm DNA (200 mg/mL) at 428CUSA). The cells were visualized with a Bio-Rad MRC-
1024 laser scanning confocal microscopy with Kr/Ar la- overnight. The cDNA probe was labeled with 32P by ran-
dom priming using Promega Prime-A-Gene Labeling Sys-ser, and images were processed on a metamorph image
analysis system. tem. After hybridization, the membranes were washed
twice with 2 3 standard saline citrate (SSC) and 0.1%For some experiments, cells were isolated from human
foreskin (the kind gift of Dr. Dan Spandau, Indiana SDS at room temperature for 30 minutes each, and twice
with 0.1 3 SSC and 0.1% SDS at 508C for 15 minutesUniversity Department of Dermatology, Indianapolis,
IN, USA) or from patients with inflammatory arthritis each. The membranes were exposed to an x-ray film
(Hyperfilm; Amersham, Arlington Heights, IL, USA)(systemic lupus erythematosus or rheumatoid arthritis)
and compared with the osteoarthritis (OA) cells. Finally, for different times. The autoradiographs were scanned,
and densitometric analysis was performed using meta-cells were incubated in the presence and absence of doxy-
cycline (Sigma) to determine whether this anti-arthritis morph software (Universal Imaging Corporation). The
membranes were striped and reprobed with GAPDH tomedication inhibits b2m-induced MMP-1 release.
compare loading.
Measurement of MMP-1 and TIMP-1
Statistical analysisHuman synovial fibroblast-like cells isolated from
each patient were plated at 5 3 104 cells per well in a A mixed-effects analysis of variance for a randomized
complete block design model was used to tests the effects24-well plate and grown in DMEM with 20% FBS for
three days until confluent at 378C and 5% CO2. The of b2m and the b2m concentration and their interaction.
Since the fibroblast samples were obtained from severalmedia were then changed to DMEM with 3% FBS for
18 hours. The cells were then incubated in the same different patient subjects for each experiment, the sub-
ject was included in the model as a random effect. Tomedia in the presence and absence of 1, 10 and 25 mg/mL
fb2m, gb2m, and ngb2m for 24 or 48 hours. These concen- control for differences among the subjects, MMP-1 and
TIMP-1 results were expressed as the percentage of thetrations were chosen to simulate actual synovial fluid
concentrations of b2m in normal individuals, patients mean result of the control run for each subject (an exam-
ple of patient to patient variation is in Fig. 7). For eachwith severe rheumatoid arthritis, and dialysis patients,
respectively [12, 13]. MMP-1 and TIMP-1 were measured experiment presented, the results were combined from
data obtained from two to four different patients, withby two-site enzyme-linked immunosorbent assay (ELISA;
Biotrak, Inc., Arlington Heights, IL, USA) in the culture three to six per group for each of the two to four different
patients. Pair-wise comparisons among the effect levelssupernatant. The MMP-1 assay recognizes total human
MMP-1, including pro-MMP-1, free MMP-1, and that were adjusted using Tukey’s procedure for multiple com-
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parisons. For the MMP-1/TIMP-1 ratio, results were cells were examined by flow cytometry using the mono-
cyte/macrophage marker CD14. No CD14 expressioncompared with control or PMA using one-way analysis
of variance (ANOVA) with Fisher’s test for pair-wise was found, confirming pure fibroblast cultures from fourth
pass on.comparisons. The analyses were done using SPSS soft-
ware (Chicago, IL, USA) and Statview (Abacus Con- As a result of these findings, all subsequent experi-
ments were done with fourth- to seventh-pass cells tocepts, Inc., Berkeley, CA, USA). All results are ex-
pressed as mean 6 SEM. An overall significance level ensure pure fibroblast cell populations.
of 0.05 was used to test all hypotheses.
MMP-1 and TIMP-1 protein expression
Human synovial fibroblasts from four different OA
RESULTS
patients incubated for 24 hours in media with b2m at 1
Isolation and purification of b2m mg/mL had no effect on the release of MMP-1 compared
with control (control 5 100%; fb2m, 114.2 6 9.2; gb2m,The results of the SDS-PAGE and immunoblotting of
the fb2m, gb2m, and ngb2m purified from human serum 126.8 6 8.7; ngb2m, 115.3 6 9.2; P 5 NS). In contrast,
both 10 and 25 mg/mL of b2m induced a significant in-ultrafiltrate as described previously in this article are
shown in Figure 1. By SDS-PAGE, the gb2m had a crease in the release of MMP-1 at 24 hours compared
with control (P , 0.01; Fig. 3). The release of MMP-1slightly higher molecular weight compared with fb2m and
ngb2m because of the formation of glucose adducts. All at 25 mg/mL was slightly greater than that observed at
10 mg/mL, although this did not reach statistical signifi-three types of b2m reacted with the anti-human b2m, but
only the glycated reacted with the anti-AGE Ab (Fig. cance. There was no difference between fb2m, gb2m, and
ngb2m at any concentration (at 10 mg/mL: fb2m, 183.2 61). In addition to these results, the gb2m, but not the
ngb2m or fb2m, fluoresced at 400 nm with excitation at 13.8; gb2m, 170.2 6 19.7; ngb2m, 163.8 6 18.6% control;
at 25 mg/mL: fb2m, 211.3 6 18.4; gb2m, 196.6 6 20.3;325 nm, typical for glycated proteins (data not shown)
[9]. In addition to its apparent purity by SDS-PAGE, ngb2m, 190.7 6 32.8% control; Fig. 3). PMA, a known
potent stimulator of MMP-1, was used as a positivesubsequent Western blots with appropriate controls
failed to demonstrate any contamination of the b2m with control for each experiment and increased the release
of MMP-1 to a similar magnitude as 25 mg/mL of b2mIL-1b, IL-6, or TNF-a. For comparison purposes, b2m
purified from human urine (Cortex Biochemicals, San (PMA 5 243.6 6 16.1; Fig. 3).
There was no difference in the release of TIMP-1 fromLeandro, CA, USA) was also used and glycated as dis-
cussed previously in this article. The two sources of b2m synovial fibroblasts in the presence or absence of b2m
at any concentration nor any difference among fb2m,had a similar appearance on SDS-PAGE (Fig. 1). Fur-
thermore, there was no difference in the results obtained gb2m, and ngb2m at equivalent concentrations. However,
there was a significant release of TIMP-1 in synovialfrom the b2m purified from plasma ultrafiltrate or that
obtained from urine for MMP-1 release, TIMP-1 release, fibroblasts incubated in the presence of 1028 mol/L PMA
compared with control (Fig. 4). As a result, comparedor Northern analysis. Thus, the results were pooled, but
the b2m isolated from ultrafiltrate accounted for greater with control, the ratio of MMP-1/TIMP-1 was signifi-
cantly increased at both 10 and 25 mg/mL of b2m (Fig.than 95% of the results for each experiment presented
in this manuscript. 5), but not in the presence of PMA.
At 48 hours, the type of b2m, the concentration of
Isolation and characterization of primary human b2m, and their interaction had a significant effect on
synovial fibroblasts MMP-1 release. Post hoc analyses demonstrated that the
incubation of synovial fibroblasts from OA patients inHuman synovial fibroblasts were isolated from OA
synovium. By immunofluorescent microscopy, the local- the presence or absence of 10 mg/mL fb2m and ngb2m
similarly increased the release of MMP-1, but there wasization of the antibodies were characteristic: CD68 local-
ized to the cytoplasm characteristic of macrophage-like no effect observed in the presence of gb2m (10 mg/mL:
fb2m, 123.6 6 5.6; gb2m, 99.7 6 5.3; ngb2m, 126.5 6 4.5%cells and VCAM-1 to dendritic processes of fibroblast
like cells. At pass one, approximately 80% of cells were control; P , 0.02, fb2m and ngb2m compared with control
and gb2m). There was a similar, but greater responsecharacteristic of macrophage-like cells and 20% charac-
teristic of fibroblast-like cells. As passages continued, observed at 25 mg/mL (fb2m, 153.8 6 5.4; gb2m, 98.1 6
8.3; ngb2m, 149.9 6 9.5% control, P , 0.001, fb2m andthe proportion of fibroblasts increased to 80 to 90% by
pass 3 (Fig. 2). Supporting these immunohistochemical ngb2m compared with control and gb2m; Fig. 6). Thus,
there was a similar dose response to fb2m and ngb2m atfindings were the results of the UDPGH enzyme assay:
Very few cells stained positive at first pass, whereas al- 24 and 48 hours. However, gb2m only elicited a release
of MMP-1 at 24 hours. Similar to the results observedmost all cells were positive by the third pass (data not
shown). As a final test of cell purity, fourth-pass synovial at 24 hours, there was no change in the release of TIMP-1
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Fig. 1. Isolation and purification of b2-micro-
globulin (b2m) from human serum ultrafil-
trate. Ultrafiltrate was collected from a long-
standing dialysis patient, and b2m was purified
as detailed in the text. The pure b2m was then
left unaltered (fb2m), incubated for 60 days at
378C in the presence of 200 mmol/L d-glucose
(gb2m) or incubated for 60 days at 378C in the
absence of glucose as a control for the incuba-
tion process (ngb2m). The three proteins were
then loaded at 20 mg/lane and run on a 15%
SDS-PAGE and transferred to nitrocellulose
and incubated with anti-b2m and anti-AGE
antibodies. As positive controls, fresh, glycated,
and nonglycated bovine serum albumin (fBSA,
gBSA, ngBSA), which were similarly prepared,
were run for comparison purposes. In addition,
b2m isolated from urine (Cortex, Inc.) was also
run for comparison of purity. The resultant
Coomassie stained gel and Western blots are
shown (A–C). All three forms of the b2m iso-
lated from ultrafiltrate were detectable by the
anti-b2m antibody, and the glycated b2m
showed the expected slight increase in molec-
ular weight. In contrast, only the gb2m and
gBSA were detected by the anti-AGE anti-
body.
Moe et al: b2m induces metalloproteinase expression2028
Fig. 2. Isolation of human synovial fibroblasts. Human synovium obtained from operative specimens were minced and digested, and the resultant
cells were cultured. The cells were then immunostained with anti-human CD68 as a marker for monocyte/macrophage-like cells or anti-human
VCAM-1 as a marker for fibroblast-like cells. Controls indicate immunostaining without the primary antibodies. The results demonstrate the
predominance of monocyte-like cells in first passage and fibroblast-like cells by third pass. (Reproduction of this figure in color was made possible
by Amgen, Inc., Thousand Oaks, CA, USA).
at 48 hours in the presence of fb2m, gb2m, or ngb2m at fibroblasts. The basal release of MMP-1 was different
depending on the underlying cell source or disease stateany concentration, leading to an increase in the MMP-
1/TIMP-1 ratio for both 10 and 25 mg/mL of fb2m and (Fig. 7). The greatest basal release was seen in a patient
with rheumatoid arthritis, although one patient with angb2m, but not gb2m (data not shown).
diagnosis of OA also had elevated basal release of
Comparison of fibroblasts from different sources MMP-1. Thus, the basal release may be more of a factor
of severity of arthritic changes, rather than of the actualTo determine whether the underlying disease of pa-
tients from whom synovial fibroblasts were isolated af- diagnosis. Despite the variation in basal release, these
results demonstrate that b2m has a similar effect on thefected the response to 10 mg/mL b2m, synovial fibroblasts
isolated from patients with various surgical diagnoses release of MMP-1 from all types of human synovial and
skin fibroblasts (P , 0.02 for each patient, except thewere compared with each other and with primary skin
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Fig. 3. Release of MMP-1 at 24 hours. Human osteoarthritic synovial
Fig. 4. Release of TIMP-1 at 24 hours. Human osteoarthritic synovialfibroblasts were incubated for 24 hours in the presence of fresh, glycated,
fibroblasts were incubated for 24 hours in the presence of fresh, glycated,and nonglycated b2m at 1, 10, and 25 mg/mL, or the known MMP-1 and nonglycated b2m at 1, 10, and 25 mg/mL, or the known TIMP-1stimulator PMA (1028 mol/L), and the concentration of MMP-1 release
stimulator PMA (1028 mol/L), and the concentration of TIMP-1 releaseinto the culture supernatant was measured. b2m induced an increase in into the culture supernatant was measured. There was no differenceMMP-1 release at 10 and 25 mg/mL that was unaffected by glycation.
in the release of TIMP-1 in the presence or absence of b2m at anyThe MMP-1 released by 25 mg/mL of b2m was similar to that released concentration, nor any difference among the types of b2m at equivalentfrom PMA by t-test. Symbols are: *, compared with control; 1, com-
concentrations. However, PMA induced a large increase in TIMP-1pared with 1 mg/mL of same group (fresh, glycated, or nonglycated b2m), release (P , 0.05 compared with control by t-test) The results are fromboth P , 0.05; N 5 9 to 15 per group pooled from three to four different
three different patients with a combined N 5 9 to 15 per group. Thepatients. The dotted line represents values for control (no b2m). dotted line represents values for control (no b2m).
dialysis patient, by ANOVA). In addition, in experi-
ments with skin fibroblasts and synovial fibroblasts from
the systemic lupus erythromatosus (SLE) patient and
OA patient 3, there was also a difference between fb2m
and gb2m despite an incubation period of only 24 hours.
One dialysis patient with known b2m amyloid disease
underwent a hip-replacement surgery for a pathologic
fracture. The results of cells from this HD patient are
also shown. These cells were difficult and slow to grow,
and attempts at culturing cells from two other dialysis
patients were unsuccessful. Despite these difficulties,
there was a trend toward a response to b2m in the syno-
vial fibroblasts isolated from a HD patient.
Effect of b2m on mRNA expression for MMP-1
To determine whether the b2m-induced increase in
MMP-1 protein release was due to an increase in mRNA,
Northern blot analysis was performed on human primary
skin fibroblasts. The skin fibroblasts were used because Fig. 5. MMP-1/TIMP-1 ratio at 24 hours. Human osteoarthritic syno-
vial fibroblasts were incubated for 24 hours in the presence of fresh,of the ability to grow faster and thus obtain more RNA.
glycated, and nonglycated b2m at 1, 10, and 25 mg/mL, or the knownThe results of a representative experiment (Fig. 8) indi-
MMP-1/TIMP-1 stimulator PMA (1028 mol/L) and the concentration
cate that fb2m, gb2m, and ngb2m increased the expression of MMP-1 and TIMP-1 release into the culture supernatant was mea-
sured. The ratio was calculated using the actual measurements ofof MMP-1 at 12, 24, and 48 hours compared with control.
MMP-1 and TIMP-1. As a result of the discordant release of MMP-1The magnitude of increased expression, when calculated
and TIMP-1, the ratio of MMP-1/TIMP-1 was increased at 10 and 25
as the MMP-1/GAPDH ratio, was less for glycated as mg/mL of b2m, but was unaltered in the presence of PMA. These
results indicate that b2m induces collagenolysis from human synovialcompared with fresh and nonglycated at all time points.
fibroblasts. Symbols are: *, compared with control; 1, compared withPMA also induced a large increase in the mRNA for
1 mg/mL of same group (fresh, glycated, or nonglycated b2m), both P ,
MMP-1 that was much greater than that observed for 0.05; N 5 9 to 15 per group pooled from 3 to 4 different patients.
b2m. Thus, PMA induced a more potent increase in
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Fig. 7. Effect of b2m on different sources of fibroblasts. Fibroblasts
isolated from different sources were incubated in the presence or ab-
sence of fresh, glycated, or nonglycated b2m at 10 mg/mL for 24 hours,
Fig. 6. Release of MMP-1 at 48 hours. Human osteoarthritic synovial and the release of MMP-1 was measured. This graph demonstrates the
fibroblasts were incubated for 48 hours in the presence of fresh, glycated, variability in the basal release of MMP-1 between patients, regardless of
and nonglycated b2m at 1, 10, and 25 mg/mL, and the concentration of diagnoses (discussed in the text). Abbreviations are: OA, osteoarthritis;
MMP-1 released into the culture supernatant was measured. Both fresh RA, rheumatoid arthritis; SLE, systemic lupus erythromatosus patient
and nonglycated b2m induced an increase in MMP-1 release at 10 and with avascular necrosis; SKIN, primary skin fibroblasts; and HD, syno-
25 mg/mL. However, glycated b2m failed to induce the release of MMP-1 vial fibroblasts from a HD patient with known b2m amyloidosis and
above basal values at any concentration. Symbols are: *, compared with femoral neck fracture. The results for each fibroblast type are presented
control; 1, compared with glycated b2m at the same concentration; all as mean 6 SEM for four to six for each group for a single patient.
P , 0.05 for N 5 9 to 12 per group, pooled from 3 different patients. Thus, b2m induces the release of MMP-1, but the absolute value of
The dotted line represents values for control (no b2m). MMP-1 is dependent on basal release of MMP-1.
mRNA MMP-1 expression, but a similar increase in and are thus believed to be one of the main etiologic
MMP-1 protein expression. The latter is likely due to factors of bone destruction in rheumatoid arthritis [30, 31].
concomitant increase in TIMP-1 protein, which may de- Synovial fluid analysis from patients with rheumatoid
grade some of the released MMP-1. Northern blot analy- arthritis reveals that the ratio of MMP-1/TIMP-1 is ele-
sis was repeated a total of two to five times at each time vated and that the ratio correlated with collagenolytic
point, with similar results. activity in in vitro assays [31]. In cultured synovial ex-
plants taken from rabbits with proliferative arthritis, the
Effect of doxycycline on b2m-induced MMP-1 release induction of the lesion correlated with no reduction in
Tetracyclines inhibits MMP-1 activity through unclear the synthesis of TIMP-1 but an increase in the synthesis
post-translational effects and have proved useful for the of MMP-1 [32]. In b2m amyloid deposits, there is erosion
treatment of rheumatoid and OA [20, 21]. To determine of cartilage, joint capsule, and bone with increased im-
whether doxycycline can inhibit the release of MMP-1 munostaining for proteinase inhibitors [5, 6], implying
induced by 10 mg/mL b2m, we incubated OA synovial increased collagenolytic/proteolytic activity. Ohashi et al
fibroblasts in the presence of increasing concentrations examined metalloproteinase immunostaining in dialysis
of doxycycline for 24 hours. As previously demonstrated, patients’ b2m amyloid deposits and found that MMP-1
was the most abundantly expressed metalloproteinase.b2m increased the expression of MMP-1 over basal (con-
By comparison, there was little expression of TIMP-1trol) values (Fig. 9). Again, there was no difference be-
[16]. These in vivo findings support our in vitro findingstween the effects observed in the presence of fb2m, gb2m,
of increased MMP-1/TIMP-1 protein ratio from humanand ngb2m. Doxycycline inhibited this release in a dose-
synovial fibroblasts in response to b2m. Thus, in dialysisdependent manner, regardless of the type of b2m (P ,
patients, b2m may stimulate the release of MMP-1 from0.001).
synovial fibroblasts, saturating the existing inhibitor
TIMP-1. This uncontrolled collagenolysis may be at least
DISCUSSION partly responsible for the bone cysts and erosions ob-
The results of this study demonstrate that b2m, in served in b2m amyloidosis.
physiologically relevant concentrations, induces the re- Our results in human synovial fibroblasts expand on
lease of MMP-1 protein and gene expression. However, earlier work by Brinckerhoff et al in rabbit synovial
there is not a concomitant increase in its naturally oc- fibroblasts treated with phorbol esters [33]. These studies
curring inhibitor, TIMP-1. Metalloproteinases are known found an increase in collagenase transcription and syn-
thesis in response to phorbol esters and the productionto enhance the degradation of bone and cartilage [28, 29],
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Fig. 8. Northern blot. Human skin fibroblasts
were incubated in the absence of b2m (con-
trol), in fresh b2m (fb2m), glycated b2m (gb2m),
nonglycated b2M (ngb2m, all at 10 mg/mL) and
in PMA (1028 mol/L) for 12, 24, and 48 hours.
Total RNA was isolated, and Northern blot
analysis was performed as detailed in the text
using MMP-1 and GAPDH probes. The re-
sults demonstrate that b2m and PMA increase
the expression of MMP-1 at all time points.
Densitometric analysis showed that the gb2m
had decreased expression compared with both
fb2m and ngb2m.
of two proteins: one 80% homologous to human b2m and in part, be due to the low concentrations of b2m used (1
to 5 mg/mL) [34].the other 60% homologous to human serum amyloid A
(SAA) protein. These latter two proteins functioned as Synovial fibroblasts secrete MMP-1 in response to a
number of stimuli such as IL-1 and phorbol esters (PMA)autocrine factors, further stimulating the release of MMP-1
from rabbit fibroblasts [33]. Human b2m and human [35–37]. The tissue specificity of MMP-1 gene activation
in response to these cytokines and PMA involves theSAA also stimulated the release of MMP-1 from the
rabbit fibroblasts [33]. Similar to our findings of increased interaction of activator protein-1 (AP-1) with other cis-
acting sequences in the promoter and with transcriptionMMP-1, Migita et al found increased MMP-3 (stromely-
sin) without increased TIMP-1 in human synovial fibro- factors, c-fos and c-jun, that bind these sequences [38, 39].
MMP-1 gene expression is regulated at multiple pointsblasts incubated with b2m. However, they were unable
to find increased MMP-2 (gelatinase) release, which may, that require both transcriptional and post-transcriptional
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duce MMP-1 in response to b2m. However, we also found
that skin fibroblasts release MMP-1 in response to b2m.
Why then are articular manifestations more common in
b2m amyloidosis? One potential explanation is that b2m
is trapped in the synovial space, exposing synovial cells
to high concentrations of b2m. The daily production rate
of b2m is approximately 230 mg/day, and unfortunately,
attempts at removal of b2m with high-flux dialysis cannot
keep up with the production rate [43]. Furthermore, no
significant extrarenal sites of catabolism are known. Given
this positive mass balance, approximately 2100 g of b2m
is retained over 25 years [43], and thus, serum levels of b2m
should rise substantially with years on dialysis. However,
serum b2m levels do not rise with time on dialysis and do
Fig. 9. Human OA synovial fibroblasts were incubated for 24 hours in not correlate with disease activity [1, 4, 43, 44]. Therefore,
the presence of 10 mg/mL of fresh, glycated, or nonglycated b2m at 10
b2m must accumulate over time in extravascular com-mg/mL, with and without increasing concentrations of the inhibitor of
MMP-1, doxycycline (doxy). The concentration of MMP-1 release into partments, such as the synovial space. The synovial space
the culture supernatant was measured. b2m without doxycycline induced is separated from the extravascular space by a simple
a significant release of MMP-1 over basal (control 5 no b2m) values membrane that allows free flux of fluid into the synovialwith no difference among the type of b2m. Doxycycline inhibited the
b2m induced release of MMP-1 in a dose-dependent manner (P , 0.01). space. Synovial fluid levels of b2m in dialysis patients are
This inhibition was observed irrespective of whether the b2m was fresh, 25 to 50 mg/mL and 5 to 10 mg/mL in rheumatoid arthritis
glycated, or nonglycated. Symbols are: *, compared with without doxy-
patients [12, 13], concentrations stimulating MMP-1 incyline for same type of b2m, N 5 7 to 8 per group for 2 patients. The
dotted line represents values for control (no b2m or doxycycline). the present study. Some of the b2m may become trapped
in the synovium because of the binding of b2m to collagen
[17] and hyaluronan (personal observations). Thus, early
manifestations may be due to this “trapping” of b2m,
mechanisms [39]. In addition, some cytokines also in- with release of MMP-1 (as in the present study), and
crease the stability (half-life) of the MMP-1 transcripts release of IL-1 [45, 46], both leading to bone destruction.
[40]. The mechanism by which b2m induces MMP-1 is In addition, we hypothesize that similar to rheumatoid
likely equally complex, with the potential differences arthritis, the stimulation of synovial fibroblasts by b2m
between fb2m and gb2m further complicating the issue. may also induce expression of adhesion molecules that
The mechanism of uptake of b2m in fibroblasts is un- may attract macrophages to the joint. The presence of
known, but uptake in the proximal tubule and hemato- macrophages, observed histologically late in the disease
poietic cells is mediated through endocytosis [41]. In course, may augment this cascade, leading to even more
contrast, proteins altered with AGE are taken up by cytokine release and bone destruction. Clearly, further
the receptor for AGE (RAGE) and appear to activate work is required to understand how b2m amyloid deposi-
nuclear factor-kB [42]. Owen et al found that skin fibro- tion occurs, the precise sequence of events, and why it
blasts had a decrease in collagen production in response occurs in nonarticular tissues late in the disease course.
to AGE-b2m, but only after 48 hours. This delayed effect Common therapies for articular diseases, such as metho-
was also observed with other AGE-proteins and could trexate and corticosteroids, are known to inhibit the re-
be blocked with antibodies to RAGE [10]. It is interest- lease of MMP-1 [30]. Of note is the dramatic improve-
ing that our observed differences in MMP-1 release be- ment of clinical symptoms in b2m amyloidosis observed
tween fb2m and gb2m may not only be time dependent immediately post-renal transplant, perhaps in response
but also dependent on the patient source for the fibro- to steroids [47]. One other therapy that has gained recent
blasts. In the present study, we found AGE-b2m stimu- recognition is tetracyclines. These agents block the re-
lated MMP-1 synthesis at 24 hours but not 48 hours lease of MMP-1 by unknown mechanisms. However, ther-
(Figs. 5 and 6), with decreased mRNA expression with apy with doxycycline in dogs [20] and minocycline in
gb2m compared with fb2m and ngb2m. However, some humans [21] has proved effective in not only reducing
individual patients showed this difference at 24 hours joint erosions, but in improving symptoms as well. We
(Fig. 7). Deciphering these interesting cellular mecha- have demonstrated that doxycycline can inhibit the re-
nisms will require further research and might help to lease of MMP-1 induced by b2m. Whether this exciting
explain the apparent stimulatory effect of AGE-b2m in finding has clinical implications in patients suffering from
monocytes/macrophages [9] and inhibitory effects in fi- b2m amyloidosis remains to be seen.
broblasts [10]. In conclusion, we have demonstrated that b2m induces
collagenolytic activity in human synovial fibroblasts. WeOur studies demonstrate that synovial fibroblasts pro-
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